Immune checkpoint inhibitors targeting three distinct molecules (CTLA-4, PD-1 as well as its ligand PD-L1) have been approved by the US Food and Drug Administration for use in humans, improving the prognosis of patients with CM [5, 35]. The gene discussed is CD274; the disease is cutaneous mastocytosis.